Add 2 More Reports For 20% off

Report Overview

Cytokine release syndrome (CRS), also known as cytokine storm or cytokine-associated toxicity, is a severe clinical syndrome characterized by drastic elevation of inflammatory cytokines. This potentially life-threatening condition can be triggered by infections and certain types of immunotherapies. Various studies suggest that 43 to 100% of study patients affected by leukemia or lymphoma, who receive CAR-T cell therapy targeted to CD19, are affected by cytokine release syndrome.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Cytokine Release Syndrome Epidemiology Forecast Report Coverage

Expert Market Research's “Cytokine Release Syndrome Epidemiology Forecast Report 2024-2032” offers comprehensive information on the prevalence and demographics of cytokine release syndrome. It projects the future incidence and prevalence rates of cytokine release syndrome across various populations. The study covers age and type as major determinants of the cytokine release syndrome-affected population. The report highlights patterns in the prevalence of cytokine release syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of cytokine release syndrome in the 8 major markets.

Regions Covered

  • The United States
  • Germany
    • France
    • Italy
    • Spain
    • The United Kingdom
  • Japan
  • India

Cytokine Release Syndrome: Disease Overview

In cytokine release syndrome, an individual's immune system aggressively responds to immunotherapy drugs or infection due to the rapid release of a large amount of cytokines in the blood. Cytokine release syndrome is primarily linked to chimeric antigen receptor (CAR)-T cell therapy but is also observed to occur with bispecific T cell engager therapy and monoclonal antibody-based therapy. Cytokine storms can impact multiple organs, with the symptoms ranging from mild (flu-like symptoms) to severe (low blood pressure, high fever, difficulty in breathing, and multi-organ failure).

Cytokine Release Syndrome: Treatment Overview

The treatment plan for this systemic inflammatory response depends on the grade of cytokine release syndrome. For Grade 2 CRS, moderate therapeutic interventions such as fluids or vasopressors for hypotension are sufficient to manage the symptoms. Grade 3 CRS needs aggressive intervention like high doses or multiple vasopressor drugs for hypotension. In Grade 4 CRS, immunosuppressants and mechanical ventilation are required.

Epidemiology

The cytokine release syndrome epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for cytokine release syndrome by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cytokine release syndrome and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

  • According to the systematic literature review published in Hematology, Transfusion and Cell Therapy (2024), a high incidence of cytokine release syndrome was reported in diffuse large B-cell lymphoma (DLBCL) patients receiving CAR T-cell therapy. The study also revealed that CRS affected 67% of the 1193 patients receiving CAR T-cell therapy, with 10% of the patient pool developing Grade 3 CRS and 3% developing Grade 4 CRS.
  • Research shows that the occurrence of cytokine release syndrome is significantly dependent on the CAR T-cell product used. For instance, studies using lisocabtagenemaraleucel report around 45% of CRS occurrence whereas treatment with tisagenlecleucel and axicabtageneciloleucel has reported about 63% and 90% CRS occurrence, respectively.
  • Various studies suggest that 43% to 100% of study patients with lymphoma or leukemia, who are treated with CAR T-cell therapy targeted to CD19, are affected by cytokine release syndrome.
  • A 2023 study on patients with relapsed/refractory multiple myeloma revealed that 119 out of 165 patients (72.1%) receiving Teclistamab (a B-cell maturation antigen × CD3 bispecific antibody) developed cytokine release syndrome.

Country-wise Cytokine Release Syndrome Epidemiology

The cytokine release syndrome epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cytokine release syndrome varies significantly between countries due to several factors that influence its prevalence, diagnosis, and management. A higher incidence of this systemic inflammatory response is reported in countries with greater access to advanced treatments such as CAR T-cell therapies and other immunotherapeutic options. Moreover, regions with a higher burden of hematological malignancies also tend to observe more cases of cytokine release syndrome.

Country Specific Stats:

Country

Prevalence (Unit)

United States

XX

United Kingdom

XX

Germany

XX

Italy

XX

France

XX

Spain

XX

Japan

XX

India

XX

Scope of the Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cytokine release syndrome based on several factors.
  • Cytokine Release Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The report helps to identify the patient population, and the unmet needs of cytokine release syndrome are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

  • What are the key findings of cytokine release syndrome epidemiology in the 8 major markets?
  • What will be the total number of patients with cytokine release syndrome across the 8 major markets during the forecast period?
  • What was the country-wise prevalence of cytokine release syndrome in the 8 major markets in the historical period?
  • Which country will have the highest number of cytokine release syndrome patients during the forecast period of 2024-2032?
  • Which key factors would influence the shift in the patient population of cytokine release syndrome during the forecast period of 2024-2032?
  • What are the currently available treatments for cytokine release syndrome?
  • What are the disease risks, signs, symptoms, and unmet needs of cytokine release syndrome?

Related Reports

Global Immunotherapy Drugs Market

Global CAR T-Cell Therapy Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2023

Historical Period

2017-2023

Forecast Period

2024-2032

Geographies Covered

  • United States
  • Germany
    • Italy
    • France
    • Spain
    • United Kingdom
  • Japan
  • India

Purchase Full Report

Datasheet

 

USD 2,199

USD 1,999

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 3,299

USD 2,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 4,399

USD 3,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124